HC Wainwright Reiterates “Buy” Rating for Incyte (NASDAQ:INCY)

Incyte (NASDAQ:INCY)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They currently have a $135.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 34.00% from the company’s previous close.

Several other research firms also recently issued reports on INCY. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $107.00 price target (down previously from $116.00) on shares of Incyte in a research note on Tuesday, January 20th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Incyte in a research report on Thursday, January 22nd. TD Cowen reaffirmed a “buy” rating on shares of Incyte in a report on Tuesday, January 13th. Barclays increased their price target on Incyte from $115.00 to $116.00 and gave the company an “overweight” rating in a research note on Wednesday, February 4th. Finally, Guggenheim upgraded Incyte from a “neutral” rating to a “buy” rating and set a $125.00 price objective for the company in a research report on Monday, November 3rd. Nine equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Incyte has a consensus rating of “Hold” and a consensus price target of $103.94.

Incyte Price Performance

Incyte stock opened at $100.75 on Wednesday. The stock has a 50-day moving average price of $101.75 and a two-hundred day moving average price of $93.86. Incyte has a 12 month low of $53.56 and a 12 month high of $112.29. The company has a market capitalization of $20.05 billion, a PE ratio of 15.72, a P/E/G ratio of 0.59 and a beta of 0.82. The company has a current ratio of 3.32, a quick ratio of 3.13 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY) last released its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, missing the consensus estimate of $1.96 by ($0.16). The firm had revenue of $1.51 billion for the quarter, compared to the consensus estimate of $1.35 billion. Incyte had a return on equity of 26.34% and a net margin of 25.03%.The business’s revenue for the quarter was up 27.8% on a year-over-year basis. During the same quarter last year, the firm posted $1.43 earnings per share. Analysts expect that Incyte will post 4.86 EPS for the current year.

Insider Activity at Incyte

In other news, insider Thomas Tray sold 2,774 shares of the stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $100.00, for a total transaction of $277,400.00. Following the transaction, the insider owned 22,973 shares of the company’s stock, valued at $2,297,300. This represents a 10.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Mohamed Khairie Issa sold 10,856 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $109.07, for a total value of $1,184,063.92. Following the transaction, the executive vice president directly owned 66,132 shares in the company, valued at approximately $7,213,017.24. This trade represents a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 95,225 shares of company stock worth $9,519,745 over the last three months. 17.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of INCY. Oregon Public Employees Retirement Fund raised its holdings in shares of Incyte by 0.5% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 18,870 shares of the biopharmaceutical company’s stock worth $1,864,000 after acquiring an additional 100 shares during the last quarter. Bank of Nova Scotia raised its stake in shares of Incyte by 0.7% in the second quarter. Bank of Nova Scotia now owns 17,041 shares of the biopharmaceutical company’s stock worth $1,160,000 after purchasing an additional 124 shares during the last quarter. MAI Capital Management lifted its holdings in shares of Incyte by 19.9% in the second quarter. MAI Capital Management now owns 754 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 125 shares in the last quarter. Atlantic Edge Private Wealth Management LLC lifted its holdings in shares of Incyte by 0.9% in the third quarter. Atlantic Edge Private Wealth Management LLC now owns 14,556 shares of the biopharmaceutical company’s stock valued at $1,235,000 after purchasing an additional 125 shares in the last quarter. Finally, Perbak Capital Partners LLP boosted its position in shares of Incyte by 2.5% during the third quarter. Perbak Capital Partners LLP now owns 5,298 shares of the biopharmaceutical company’s stock valued at $449,000 after buying an additional 129 shares during the last quarter. Institutional investors and hedge funds own 96.97% of the company’s stock.

Key Stories Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Management provided a forward-looking revenue roadmap, outlining 10–13% revenue growth for 2026 and pointing to pipeline expansion and new product launches as growth drivers — this supports a bullish medium-term revenue thesis. Article Title
• Positive Sentiment: HC Wainwright reiterated a Buy rating with a $135 target, reflecting conviction in Incyte’s long-term revenue durability and underappreciated pipeline — a catalyst for upside from some institutional investors. Article Title
• Neutral Sentiment: Q4 earnings call and transcript provide detail: revenue grew strongly (quarterly revenue +27.8% y/y and topped estimates) but EPS missed consensus — investors will parse pipeline comments and margin guidance for signs of sustainable profitability. Article Title
• Neutral Sentiment: Incyte sold Wilmington Bracebridge towers to BPG — a non-core real-estate transaction that slightly improves balance-sheet flexibility but is not material to drug revenue. Article Title
• Neutral Sentiment: Reported short-interest data appears anomalous (shows 0 shares / NaN increase and 0.0 days to cover) — treat as unreliable until clarified by exchanges. (Two entries flagged this oddity.)
• Negative Sentiment: EPS missed consensus on the quarter, prompting a gap-down reaction in shares immediately post-earnings — this short-term selling pressure explains much of the intraday volatility. Article Title
• Negative Sentiment: Royal Bank of Canada cut its price target to $92 and moved to “sector perform,” signaling reduced near-term conviction and pressure on sentiment. (Benzinga / TickerReport coverage noted.)
• Negative Sentiment: Regulatory risk: analysts flagged emerging U.S. “Most Favored Nation” drug-pricing policies as a new risk that could pressure profitability and margins over time — a tangible downside catalyst for revenue forecasts. Article Title

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.